H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on PDS Biotechnology today and set a price target of $13.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight the promising developments in PDS Biotechnology’s pipeline. The company has recently reported the start of the Phase 3 VERSATILE-003 study, which is progressing as planned, indicating strong potential for future success. Additionally, the Phase 2 PDS01ADC study for colorectal cancer has met the criteria for expansion into Stage 2, following encouraging results in Stage 1, further supporting the company’s innovative approach.
Moreover, updated results from the VERSATILE-002 study were presented at ASCO ’25, enhancing the clinical profile of Versamune HPV. The company is also expected to publish a full data set from VERSATILE-002 in late 2025 or early 2026, which could provide further validation of their technology. These advancements, coupled with a solid financial position, underscore the potential for significant growth and value generation, justifying the Buy rating.